Papillary renal cell carcinoma (pRCC) is the second most common subtype of renal cell carcinoma, accounting for 10-15% of all kidney cancers. Unlike clear cell RCC, it is a hypovascular tumor that does not demonstrate avid arterial phase enhancement; instead, it shows a homogeneous, mild, and progressive enhancement pattern. Histologically, it exhibits a papillary or tubulopapillary growth pattern. Two subtypes exist: Type 1 (small basophilic cells with thin fibrovascular cores forming papillary structures, better prognosis) and Type 2 (large eosinophilic cells with pseudostratified nuclear arrangement, more aggressive behavior). Typically occurs between ages 50-70 with a male-to-female ratio of 3:1. Hereditary papillary RCC syndrome (MET proto-oncogene mutation) can lead to bilateral and multifocal tumors. The tumor frequently demonstrates hemosiderin deposition, necrosis, and cystic degeneration; these features cause T2 hypointensity on MRI and intralesional calcification on CT. Treatment involves partial or radical nephrectomy; immunotherapy and MET inhibitors (cabozantinib) are used in metastatic disease. It generally has a better prognosis compared to clear cell RCC.
Age Range
40-80
Peak Age
62
Gender
Male predominant
Prevalence
Uncommon
Papillary RCC originates from proximal tubular epithelium and develops through two distinct molecular pathways. In Type 1 pRCC, the key genetic event is activation of the MET proto-oncogene (chromosome 7q31). MET is the hepatocyte growth factor (HGF) receptor; when activated, it stimulates cell proliferation, migration, and angiogenesis. However, MET-mediated angiogenesis produces a much lower level of vascularity compared to the VEGF pathway — this is why pRCC is hypovascular and does not exhibit the hypervascular pattern of clear cell RCC. Additionally, trisomy 7 and 17 are common in Type 1. In Type 2 pRCC, fumarate hydratase (FH) gene mutation (hereditary leiomyomatosis and renal cell carcinoma syndrome — HLRCC) or CDKN2A/SETD2 mutations play a role. FH loss leads to fumarate accumulation and HIF-alpha pathway activation, but the resulting vascularity still does not reach the level of clear cell RCC. Intratumoral hemosiderin deposition results from hemorrhage within papillary structures and accumulation of hemoglobin degradation products in macrophages — this is the cardinal finding causing T2 hypointensity on MRI through paramagnetic effects. Necrosis and cystic degeneration are related to the tumor's relative hypovascularity — insufficient blood flow leads to central ischemia. Calcification arises from dystrophic calcification of necrotic areas and carries near-pathognomonic value on CT.
Homogeneous solid renal mass showing marked hypointensity on T2-weighted MRI and enhancing less than renal parenchyma on contrast-enhanced series — the combination of hemosiderin deposition and low vascularity is the signature finding of papillary RCC. The coexistence of these two features predicts papillary RCC with 80-90% accuracy and reliably distinguishes it from clear cell RCC (T2 hyperintense + hypervascular). Particularly valuable in pre-biopsy characterization of small renal masses (<4 cm).
Homogeneous solid mass enhancing significantly less than renal parenchyma in arterial (corticomedullary) phase. Enhancement typically shows 20-40 HU increase (as opposed to >100 HU in clear cell RCC). Small tumors (<3 cm) enhance homogeneously, while larger tumors may be heterogeneous due to central necrosis. Hypovascularity is the most distinguishing CT feature of papillary RCC and is critically important for differentiation from clear cell RCC.
Report Sentence
Homogeneous hypovascular solid mass in the kidney enhancing significantly less than renal parenchyma in arterial phase; papillary renal cell carcinoma should be considered as the leading diagnosis.
Progressive increase in tumor enhancement in nephrographic and delayed phases. The tumor that mildly enhances in the arterial phase shows more prominent enhancement in the nephrographic phase, with enhancement continuing to increase in the delayed phase. This 'progressive delayed enhancement' pattern is the exact opposite of the 'early enhancement–rapid washout' pattern of clear cell RCC and is highly characteristic of papillary RCC. In the delayed phase, the tumor may still remain hypodense relative to renal parenchyma, but the significant contrast increase compared to the arterial phase is notable.
Report Sentence
The mass demonstrates progressive enhancement increase in nephrographic and delayed phases, a pattern consistent with papillary renal cell carcinoma.
Focal or coarse calcification foci within the mass on non-contrast CT. Papillary RCC is the RCC subtype most commonly associated with calcification (up to 30%). Calcifications are typically centrally located, in amorphous or coarse patterns, representing dystrophic calcification of necrotic areas. In the presence of a calcified renal mass, papillary RCC should rank high in the differential diagnosis. Non-contrast CT also provides a critical baseline reference for assessing baseline density and calculating the degree of enhancement.
Report Sentence
Coarse calcification foci are identified within the renal mass on non-contrast CT; papillary renal cell carcinoma is the RCC subtype most commonly associated with calcification.
Marked hypointensity relative to renal parenchyma on T2-weighted images. This is the most characteristic MRI finding of papillary RCC and distinctly separates it from T2 hyperintensity of clear cell RCC. The hypointensity results from intratumoral hemosiderin deposition (chronic hemorrhage in papillary structures) and high cellularity. Homogeneous T2 hypointensity is particularly prominent in Type 1 pRCC; Type 2 pRCC may be more heterogeneous due to necrosis. The combination of T2 hypointensity + hypovascularity predicts papillary RCC with high confidence.
Report Sentence
The renal mass demonstrates marked hypointensity relative to renal parenchyma on T2-weighted images, consistent with hemosiderin deposition and high cellularity, suggesting papillary renal cell carcinoma.
Focal or diffuse hyperintensity on T1-weighted images. This finding is related to methemoglobin accumulation in the subacute phase of intratumoral hemorrhage. Hemorrhages within papillary structures reaching the methemoglobin phase markedly increase T1 signal. Hyperintense areas may show heterogeneous distribution within the tumor. The combination of T1 hyperintensity + T2 hypointensity is a highly specific MRI pattern for hemorrhagic papillary RCC. Persistence of T1 hyperintensity on fat-suppressed sequences confirms that the signal originates from hemorrhagic products rather than fat.
Report Sentence
The renal mass demonstrates focal hyperintensity on T1-weighted images; persistence on fat-suppressed sequences suggests methemoglobin accumulation (subacute hemorrhage), consistent with papillary RCC.
Marked diffusion restriction on diffusion-weighted imaging (DWI) — hyperintensity at high b-values (b=800-1000) with low ADC values. Papillary RCC, due to its high cellularity and compact papillary architecture, shows among the lowest ADC values of renal tumors. Mean ADC value ranges from 1.0-1.3 × 10⁻³ mm²/s, significantly lower than clear cell RCC (1.5-2.0 × 10⁻³ mm²/s). Diffusion restriction serves as a helpful additional finding for detection of small tumors and subtype differentiation.
Report Sentence
The renal mass demonstrates marked diffusion restriction with low ADC values on diffusion-weighted imaging, consistent with high cellularity and supportive of papillary RCC.
Homogeneous mild enhancement significantly less than renal parenchyma on contrast-enhanced MRI. After gadolinium-based contrast, the tumor shows lower signal intensity than surrounding renal parenchyma. Enhancement is homogeneous, differing from the heterogeneous hypervascular pattern of clear cell RCC. Dynamic contrast-enhanced MRI shows a progressive enhancement curve — low peak with slowly rising pattern on time-intensity curve. This finding is of particular diagnostic importance in characterization of small renal masses (<4 cm).
Report Sentence
The renal mass demonstrates homogeneous mild enhancement significantly less than renal parenchyma on contrast-enhanced MRI; the hypovascular enhancement pattern is consistent with papillary renal cell carcinoma.
Homogeneous hypoechoic or isoechoic solid mass relative to renal parenchyma on B-mode ultrasonography. Papillary RCC generally appears more homogeneous than clear cell RCC on ultrasound and tends to be distinctly hypoechoic. Small papillary RCCs (<3 cm) may sometimes appear entirely hypoechoic and well-defined, potentially mimicking simple cyst or oncocytoma. Larger tumors may show mixed echogenicity due to central necrosis. Hypovascularity on Doppler ultrasound (detection of low vascularity or avascularity) supports papillary RCC. Absence of the prominent intratumoral vascularity seen in clear cell RCC on color Doppler is an important distinguishing finding.
Report Sentence
Homogeneous hypoechoic solid mass identified in the kidney on B-mode ultrasonography; no significant intratumoral vascularity detected on color Doppler, a pattern consistent with papillary RCC.
Mildly hyperdense or isodense mass relative to renal parenchyma on non-contrast CT. Papillary RCC may demonstrate higher density than renal parenchyma on non-contrast phase (45-65 HU) due to its dense cellularity and hemosiderin deposition. This finding differs from clear cell RCC, which typically appears hypodense on non-contrast phase. When spontaneous hyperdensity is present, thin-section evaluation is needed to avoid confusion with calcification. High baseline density on non-contrast phase combined with low enhancement in contrast phases carries diagnostic value for papillary RCC.
Report Sentence
The renal mass appears mildly hyperdense relative to renal parenchyma on non-contrast CT, consistent with dense cellularity and hemosiderin deposition, supporting papillary RCC.
Criteria
Small basophilic cells, papillary structures with thin fibrovascular cores, frequently macrophages and psammoma bodies, Fuhrman grade 1-2, MET gene activation, trisomy 7 and 17
Distinct Features
On imaging: smaller size, more homogeneous enhancement, more uniform T2 hypointensity, less necrosis. Better prognosis — 5-year survival rate 80-90%. Greater tendency for multifocal and bilateral presentation (in hereditary form). Male-to-female ratio up to 5:1. Typically presents at low stage and low grade.
Criteria
Large eosinophilic cells, pseudostratified nuclear arrangement, prominent nucleoli, Fuhrman grade 3-4, CDKN2A/SETD2 mutations or FH mutation (HLRCC syndrome), CpG island methylation
Distinct Features
On imaging: larger size, more heterogeneous structure, prominent necrosis and hemorrhage, cystic degeneration more frequent. More aggressive behavior — 5-year survival rate 50-60%, higher metastasis risk (lung, bone, liver). Renal vein invasion more common. In HLRCC-associated form, may present as unilateral large tumor, diagnosed at younger age (20-40). More heterogeneous T2 signal on MRI.
Criteria
Fumarate hydratase (FH) gene mutation, hereditary leiomyomatosis and renal cell carcinoma syndrome, autosomal dominant inheritance, associated with cutaneous and uterine leiomyomas
Distinct Features
Typically presents as single large aggressive tumor in young adults (20-40). Type 2 morphology but more aggressive — may metastasize early. Prominent eosinophilic nucleoli (viral inclusion-like). May be indistinguishable from other papillary RCC on imaging, but HLRCC should be considered when a large hypovascular renal mass occurs in a young patient. FH mutation screening is performed with genetic counseling. Cutaneous leiomyomas and early-onset uterine leiomyomas in women are clinical clues.
Criteria
Germline MET proto-oncogene mutation (7q31), autosomal dominant inheritance, bilateral and multifocal Type 1 papillary RCC, typically becomes clinically apparent in 5th and 6th decades
Distinct Features
On imaging: bilateral and multifocal small renal masses — multiple hypovascular lesions in both kidneys. Type 1 morphology with more indolent behavior. Microscopic tumor foci may be widespread in surgical specimens. Nephron-sparing approach (active surveillance + selective partial nephrectomy) is preferred — bilateral nephrectomy is avoided if possible. The 3 cm rule: surgery is considered when tumors reach 3 cm. MET inhibitors (foretinib, cabozantinib) can be used in metastatic disease.
Distinguishing Feature
Clear cell RCC shows prominent hypervascular enhancement in arterial phase (>100 HU increase) with rapid washout in nephrographic phase; papillary RCC is hypovascular with mild progressive enhancement. On MRI, clear cell RCC is T2 hyperintense while papillary RCC is T2 hypointense. Clear cell RCC may show signal drop on opposed-phase due to intracellular lipid.
Distinguishing Feature
Chromophobe RCC shows homogeneous moderate enhancement (more than papillary RCC, less than clear cell RCC). On MRI, it may show homogeneous mild T2 hypointensity but not as pronounced as papillary RCC. Segmental enhancement pattern (spoke-wheel) is more specific to chromophobe RCC. Chromophobe RCC does not calcify and may contain a central scar. Genetically, losses of chromosomes 1, 2, 6, 10, 13, 17, 21 are typical.
Distinguishing Feature
Oncocytoma shows homogeneous and avid enhancement (more vascularity than papillary RCC), central stellate scar is pathognomonic. On MRI, it is isointense or mildly hyperintense on T2 (unlike the hypointensity of papillary RCC). Segmental enhancement pattern and homogeneous delayed enhancement are seen. Definitive differentiation may sometimes require biopsy — oncocytic cells and absence of mitoses are diagnostic on histology.
Distinguishing Feature
Fat-poor AML may be hypovascular and mimic papillary RCC. However, fat-poor AML shows very pronounced T2 hypointensity (even darker than papillary RCC — due to smooth muscle content). No signal drop on opposed-phase (no intracellular lipid). Shows homogeneous enhancement. More common in women (4:1) and may be associated with tuberous sclerosis. Definitive differentiation usually requires biopsy — HMB-45 positivity is diagnostic of AML.
Distinguishing Feature
Collecting duct carcinoma has medullary location (originates from renal medulla — papillary RCC is usually cortical), shows infiltrative growth pattern with irregular margins. May be hypovascular but heterogeneous enhancement and prominent renal sinus invasion are notable. Younger age (30-40) and sickle cell disease association are important clinical clues. May be T2 hypointense on MRI but the infiltrative pattern and medullary location distinguish it from papillary RCC.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
6-monthPapillary RCC is the second most common RCC subtype after clear cell RCC and requires surgical treatment. For small tumors (<4 cm, T1a), partial nephrectomy (nephron-sparing surgery) is preferred; radical nephrectomy is performed for larger tumors. Biopsy is recommended especially for characterization of small renal masses to determine subtype and guide treatment planning — confirmation of papillary RCC may influence the decision for active surveillance (safer in Type 1). In hereditary forms (MET mutation, HLRCC), nephron-sparing approach and the 3 cm rule are important due to bilateral involvement potential. In metastatic disease, immunotherapy (nivolumab+ipilimumab), MET inhibitors (cabozantinib, savolitinib), and mTOR inhibitors are treatment options. Prognosis is generally better than clear cell RCC — 5-year survival 80-90% for Type 1, 50-60% for Type 2. Post-surgical follow-up: CT/MRI every 6 months for the first 2 years, then annual imaging is recommended.
Papillary RCC generally has better prognosis than clear cell RCC. Type 1 is low grade with better prognosis, while Type 2 is high grade and more aggressive. May be multifocal/bilateral. May be associated with hereditary papillary RCC syndrome (MET mutation).